Crinetics Pharmaceuticals, Inc. (CRNX): Price and Financial Metrics


Crinetics Pharmaceuticals, Inc. (CRNX): $18.85

0.20 (+1.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CRNX Stock Price Chart Interactive Chart >

Price chart for CRNX

CRNX Price/Volume Stats

Current price $18.85 52-week high $28.95
Prev. close $18.65 52-week low $15.91
Day low $18.25 Volume 209,600
Day high $19.10 Avg. volume 303,714
50-day MA $18.93 Dividend yield N/A
200-day MA $21.62 Market Cap 1.01B

Crinetics Pharmaceuticals, Inc. (CRNX) Company Bio


Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is based in San Diego, California.


CRNX Latest News Stream


Event/Time News Detail
Loading, please wait...

CRNX Latest Social Stream


Loading social stream, please wait...

View Full CRNX Social Stream

Latest CRNX News From Around the Web

Below are the latest news stories about Crinetics Pharmaceuticals Inc that investors may wish to consider to help them evaluate CRNX as an investment opportunity.

Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in a fireside chat at the annual SVB Leerink Global Healthcare Conference, which is being held in a virtual format February 14-18, 2022. Details of the presentation are as fol

Yahoo | February 9, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on February 1, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 135,000 shares of its common stock to seven new non-exe

Yahoo | February 1, 2022

What Kind Of Investors Own Most Of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)?

A look at the shareholders of Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) can tell us which group is most powerful...

Yahoo | January 24, 2022

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference

- Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 - Initiation of patient dosing in a Phase 2 trial of paltusotine in carcinoid syndrome associated with neuroendocrine tumors expected in 2022 - - Initiation of IND-enabling studies for parathyroid receptor type-1 antagonist expected in 2022 - SAN DIEGO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Scott Struthers, Ph.D. , founder & CEO of Crinetics, will provide a company update at the 40 th annual J.P. Morgan Healthcare Conference today, Wednesday, January 12 th at 4:...

Benzinga | January 12, 2022

Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...

Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..

Yahoo | December 28, 2021

Read More 'CRNX' Stories Here

CRNX Price Returns

1-mo 4.72%
3-mo -20.06%
6-mo -33.42%
1-year -5.75%
3-year -23.68%
5-year N/A
YTD -33.65%
2021 101.35%
2020 -43.76%
2019 -16.34%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6961 seconds.